https://orcid.org/0000-0001-5141-1000
References
- The Japan Glaucoma Society. Guidelines for Glaucoma. 4th ed. Nippon Ganka Gakkai Zasshi. 2018;122:5–53. Japanese.
- Djafari F, Lesk MR, Harasymowycz PJ, Desjardins D, Lachaine J. Determinants of adherence to glaucoma medical therapy in a long-term patient population. J Glaucoma. 2009;18(3):238–243. doi:10.1097/IJG.0b013e3181815421
- Nakai Y, Inoue K, Moriyama R, Wakakura M, Inoue J, Tomita G. Current status of glaucoma therapy at private practices and a private ophthalmology hospital. Atarashii Ganka. 2008;25:1581–1585. Japanese.
- Nagai M, Higa R, Shiokawa M, Inoue K, Ishida K, Tomita G. Current status of therapy for glaucoma at multiple ophthalmic institutions in 2016. Atarashii Ganka. 2017;34:1035–1041. Japanese.
- Inoue K, Nagai M, Arai Y, Shiokawa M, Ishida K, Tomita G. Current status of therapy for glaucoma at multiple ophthalmic institutions in 2016: fixed combination eye drops. Rinsho Ganka. 2017;71:1743–1754. Japanese.
- Shiokawa M, Inoue K, Tomita G. Current status of glaucoma therapy at private practices and private ophthalmology hospital in 2012. Atarashii Ganka. 2013;30:851–856. Japanese.
- Kuroda A, Inoue K, Inoue J, Kunimatsu-Sanuki S, Ishida K, Tomita G. Multi-institutional survey for glaucoma in 2020-drug therapy. Rinsho Ganka. 2021;75:377–385. Japanese.
- Joh HJ, Jin SW. Comparison of different combinations of maximum medical therapy for lowering intraocular pressure in primary open angle glaucoma: 12-month retrospective consecutive case series. Jpn J Ophthalmol. 2019;63(4):322–327. doi:10.1007/s10384-019-00673-8
- Hashimoto Y, Kitamoto K, Aihara M, Usui T. Toxicity profiles of fixed-combination eye drops for glaucoma therapy using cultivated human corneal epithelial sheets. Jpn J Ophthalmol. 2020;64(3):304–311. doi:10.1007/s10384-020-00742-3
- Xing Y, Zhu L, Zhang K, Huang S. The efficacy of the fixed combination of latanoprost and timolol versus other fixed combinations for primary open-angle glaucoma and ocular hypertension: a systematic review and meta-analysis. PLoS One. 2020;15(2):e0229682. doi:10.1371/journal.pone.0229682
- Netland PA, Weiss HS, Stewart WC, Cohen JS, Nussbaum LL; Night Study Group. Cardiovascular effects of topical carteolol hydrochloride and timolol maleate in patients with ocular hypertension and primary open-angle glaucoma. Am J Ophthalmol. 1997;123(4):465–477. doi:10.1016/s0002-9394(14)70172-2
- Stewart WC, Cohen JS, Netland PA, Weiss H, Nussbaum LL; Nocturnal Investigation of Glaucoma Hemodynamics Trial Study Group. Efficacy of carteolol hydrochloride 1% vs timolol maleate 0.5% in patients with increased intraocular pressure. Am J Ophthalmol. 1997;124(4):498–505. doi:10.1016/s0002-9394(14)70865-7
- Saito Y, Kizaki J, Wada Y, Shibasaki Y, Kishimoto N, Aihara M. Comparison of the 24-h efficacy and safety of fixed combination carteolol/latanoprost and timolol/latanoprost in patients with primary open-angle glaucoma and ocular hypertension: a prospective crossover study. Jpn J Ophthalmol. 2021;65(5):598–607. doi:10.1007/s10384-021-00856-2
- Park SW, Kim JM, Lee JW, Maglambayan J, Simonyi S, Park KH. Efficacy and safety of fixed-combination brimonidine tartrate/timolol maleate in primary open-angle glaucoma, including normal-tension glaucoma. Jpn J Ophthalmol. 2021;65(2):295–305. doi:10.1007/s10384-020-00796-3